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Abstract
Iron Regulatory Protein 2 (Irp2, Ireb2) is a central regulator of cellular iron homeostasis in vertebrates. Two global knockout
mouse models have been generated to explore the role of Irp2 in regulating iron metabolism. While both mouse models
show that loss of Irp2 results in microcytic anemia and altered body iron distribution, discrepant results have drawn into
question the role of Irp2 in regulating brain iron metabolism. One model shows that aged Irp2 deficient mice develop adult-
onset progressive neurodegeneration that is associated with axonal degeneration and loss of Purkinje cells in the central
nervous system. These mice show iron deposition in white matter tracts and oligodendrocyte soma throughout the brain. A
contrasting model of global Irp2 deficiency shows no overt or pathological signs of neurodegeneration or brain iron
accumulation, and display only mild motor coordination and balance deficits when challenged by specific tests.
Explanations for conflicting findings in the severity of the clinical phenotype, brain iron accumulation and neuronal
degeneration remain unclear. Here, we describe an additional mouse model of global Irp2 deficiency. Our aged Irp2
2/2 mice
show marked iron deposition in white matter and in oligodendrocytes while iron content is significantly reduced in neurons.
Ferritin and transferrin receptor 1 (TfR1, Tfrc), expression are increased and decreased, respectively, in the brain from Irp2
2/2
mice. These mice show impairments in locomotion, exploration, motor coordination/balance and nociception when
assessed by neurological and behavioral tests, but lack overt signs of neurodegenerative disease. Ultrastructural studies of
specific brain regions show no evidence of neurodegeneration. Our data suggest that Irp2 deficiency dysregulates brain iron
metabolism causing cellular dysfunction that ultimately leads to mild neurological, behavioral and nociceptive impairments.
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Iron is essential for growth and proliferation of mammalian cells
due to its role as a protein cofactor for hemoglobin synthesis, DNA
synthesis and mitochondrial respiration. Regulation of cellular
iron content is crucial since excess cellular iron catalyzes the
generation of reactive oxygen species that damage DNA and
proteins, while cellular iron deficiency causes cell cycle arrest and
cell death. Dysregulation of iron homeostasis caused by iron excess
or iron deficiency leads to hematological, metabolic and neuro-
degenerative diseases [1–3].
The central nervous system is particularly vulnerable to
altered iron metabolism. Iron deficiency perinatally or postna-
tally can cause permanent neurocognitive and motor impair-
ments in humans [4–6] and in rodent models [7]. Abnormally
high brain iron is associated with common neurodegenerative
disorders, including Parkinson’s and Alzheimer’s diseases, as
well as rare inherited diseases known as Neurodegeneration with
Brain Iron Accumulation (NBIA) [3,8], which manifest as
movement disorders. Whether brain iron accumulation is the
primary pathologic event causing neurodegeneration or whether
iron accumulation is a secondary event caused by neuronal
death is unclear. However, two NBIA diseases, hereditary
ferritinopathy and aceruloplasminemia, caused by mutations in
the ferritin-L subunit gene (FTL) [9] and in the ceruloplasmin
(CP) gene [10], respectively, suggest that abnormal iron
metabolism is the pathologic event leading to neurodegeneration
in these disorders. These studies highlight the importance of
maintaining brain iron within a physiological range to avoid the
adverse consequences of iron depletion or excess.
Vertebrate cellular iron metabolism is regulated post-tran-
scriptionally by iron regulatory protein 1 (Irp1, also known as
Aco1) and Irp2 [11,12]. Irps are cytosolic RNA-binding proteins
that bind to iron-responsive elements (IREs) located in the 59 or
39 untranslated regions of mRNAs encoding proteins involved in
iron sequestration (ferritin) and iron uptake (TfR1), respectively.
When cells are iron-deficient, Irps bind IREs with high affinity
inhibiting ferritin translation while stabilizing TfR1 mRNA.
When cells are iron-sufficient, Irp1 is converted to an [4Fe-4S]-
containing aconitase and Irp2 is degraded by iron-mediated
proteasomal degradation [13–15], increasing ferritin translation
and promoting TfR1 mRNA degradation. Irps thus regulate the
amount of iron sequestered by ferritin and acquired by TfR1
ensuring that cells acquire adequate iron for their needs without
it reaching toxic levels. Ferritin and TfR1 are the primary Irp-
regulated target mRNAs; however, Irps regulate other IRE-
containing mRNAs that encode proteins involved in the
tricarboxylic acid cycle, heme biosynthesis, iron export, hypoxia
and the cell cycle [12,16].
Mouse models of Irp1 and Irp2 deficiency have been
generated [17–19]. Irp1
2/2 mice display polycythemia due to
derepression of the Irp1-specific target mRNA hypoxia-inducible
factor 2a (Hif-2a; also known as Epas1) [20–22]. Two mouse
models of global Irp2 deficiency display dysregulation of ferritin
and TfR1and abnormal iron content in several tissues, and
develop microcytic anemia and erythropoietic protoporphyria
[17,19,23,24]. Irp2
2/2 mice generated by LaVaute et al. [17]
developed a progressive late-onset neurodegenerative disorder
(.6 months old) characterized by tremors, abnormal gait, subtle
kyphosis and hind-limb weakness. Neurological tests showed
impaired neuromuscular performance and grooming activity in
these mice and histochemical studies showed evidence of
axonpathy in white matter that is associated with increased
ferric iron and ferritin expression [17]. The severity of
neurodegeneration and microcytic anemia is worse in Irp2
2/2
mice lacking one copy of Irp1 (Irp2
2/2;Irp1
+/2), indicating a
dosage effect [25]. In contrast, fourteen month old Irp2
2/2
mice generated by Galy et al. [26] showed no overt signs of
neurodegeneration, abnormal brain iron accumulation or
evidence of neuronal degeneration, and displayed only mild
motor coordination/balance impairments and reduced grooming
activity when assessed by neurological and behavioral tests [26].
The cause of the differences in the severity of clinical
phenotypes and neuropathology in these two Irp2
2/2 mouse
models remains unclear.
Here, we describe neurological, behavioral and brain iron
phenotypes in an additional global Irp2 deficient mouse model.
We find that our Irp2
2/2 mice recapitulate the salient features of
other Irp2
2/2 models, including microcytic anemia, erythropoietic
protoporphyria, altered body iron distribution and dysregulation
of ferritin and TfR1 in several tissues. Our aged Irp2
2/2 mice do
not display overt signs of neurodegeneration, but show mild
impairments in motor coordination/balance, locomotion and
nociception. Irp2
2/2 mice have marked iron deposition in white
matter and in oligodendrocytes, and iron deficiency in neurons
without pathological evidence of neurodegeneration. We conclude
that alterations in brain iron caused by Irp2 deficiency likely
disrupts cellular function, and causes neurological, behavioral and
nociception impairments.
Materials and Methods
Mice
The generation of Irp2
2/2 mice is described in Figure S1.
Irp2
2/2 mice were generated on a C57BL/6J and 129/Sv
background and backcrossed with C57BL/6J for five generations.
Irp2
2/2 and WT littermates were obtained from intercrosses from
Irp2
+/2 parents. Only male mice were used for this study. Mice
used for neurological and behavioral experiments were 57–
63 weeks (WT) and 38–45 weeks (Irp2
2/2) and mice used for
hematological/clinical analysis were 64–75 weeks (WT) and 49–
71 weeks (Irp2
2/2). Mice were kept in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Utah (Protocol Number:
13-02012). All mice were housed in a pathogen free environment
with water and fed mouse breeder diet containing 270 mg Fe/kg
(Teklad 8626) provided ad libitum. Mice were euthanized
according to AVMA Guidelines for the Euthanasia of Animals.
At the German Mouse Clinic, mice were maintained in IVC cages
with free access to water and standard mouse chow containing
183 mg Fe/kg (Altromin no.1324) according to the GMC housing
conditions and German laws. All tests performed at the GMC
were approved by the responsible authority of the Regierung von
Oberbayern.
Immunoblot analysis and RNA electrophoretic mobility
shift assay (RNA-EMSA)
Tissues were homogenized in lysis buffer (150 mM NaCl,
10 mM EDTA, 10 mM Tris-HCl pH 7.4, 1% Triton X-100,
1 mM DTT and Cocktail Protease Inhibitor (Roche)) and
whole-cell lysates were prepared. Protein concentration was
determined using Coomassie Plus Protein Assay Reagent
(Thermo Scientific). Lysates were analyzed by NuPAGE 4–
12% Bis-Tris Gel with MES SDS-running buffer (Invitrogen).
Proteins were transferred to a Hybond-ECL nitrocellulose
membrane (Amersham) and probed with the following antibod-
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antibody [28]; rabbit anti-ferritin-L (Ftl1) antibody (Santa Cruz);
TfR1 monoclonal antibody (Zymed); b-actin monoclonal anti-
body (Calbiochem). Horseradish peroxidase-conjugated second-
ary antibodies were bound and proteins were visualized using
Western Lighting Chemiluminescence Reagent Plus (PerkinEl-
mer Life Sciences). RNA-EMSA was performed by incubating
tissue lysate (12 ug) isolated from Irp2
2/2 and WT mice with a
32P-labeled ferritin-L IRE probe (pGL-66 linearized with Sma1)
followed by analysis of the RNA-protein complexes on
nondenaturing 5% polyacrylamide gels according to Leibold
and Munro [29]. The gels were dried and exposed to a
PhosphorImager screen for analysis.
Tissue iron content
Tissue iron content was determined by digesting tissue (20–
30 mg) in 40% metal-free nitric acid at 95uC. Samples were
diluted in water and analyzed by PerkinElmer Optima 3100XL
ICP-OES Spectrometer.
Immunohistochemistry
Male WT mice at 68–78 weeks old (n=8) and Irp2
2/2 mice at
52–73 weeks old (n=10) were perfused with Wash Buffer (0.8%
NaCl, 0.4% dextrose, 0.8% sucrose, 0.023% CaCl2, and 0.034%
sodium cacodylate) until liver was cleared, and then fixed with Fix
Buffer (4% paraformaldehyde, 4% sucrose, and 1.4% sodium
cacodylate, pH 7.4) by cardiac perfusion. Heads were amputated
and stored overnight in Fix buffer. Brains were removed and
stored in Cacodylate buffer (14.3% sodium cacodylate, pH 7.4)
before all 18 brains were embedded together in a solid block
matrix using Multi-Brain Technology (NeuroScience Associates
(NSA), Knoxville, TN). Cryostat sections (35 um) were stained
with 3,39-diaminobenzidine (DAB)-enhanced Perls’ iron stain to
detect ferric iron. Whole brain images were viewed with a Zeiss
Stemi SV6 microscope and captured with a MTI 3CCD camera.
Perls’ stained brain sections were imaged with the EVOS-FL
imaging system (Life Technologies). Quantification of Perls’ stain
in CA1 pyramidal cells and Purkinje cells was carried out by
measuring staining intensity in a defined subsection of brain
sections from Irp2
2/2 (n=10) and WT (n=8) mice using Image J
software.
Immunofluorescence
For immunofluorescence, cryostat sections were mounted on
slides and incubated in a boiled citrate-based antigen retrieval
solution (10 mM citrate pH 6.0, 0.05% Tween-20) until cooled
(20 min). Sections were blocked using 5% goat serum in Tris-
buffered saline plus 0.3% Triton X-100 for 1 h. Double
immunofluorescence staining was performed by costaining
sections with rabbit anti-rat ferritin antibody (UT106, generated
in our laboratory against rat-H- and -L liver ferritin) overnight at
4uC and the following antibodies: mouse anti-NeuN for neuronal
nuclei (1:500, MAB377, Millipore) and mouse calbindin for
Purkinje cells (1:1000, Sigma). Sections were incubated with
secondary antibodies Alexa Fluor 488 goat anti-rabbit IgG and
Alexa Fluor 594 goat anti-mouse for 1 h at room temperature.
Images were viewed with an Olympus IX81 microscope and
captured with a DP71 camera.
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from 9.5–10.5 day embryos using
TRIzol reagent (Invitrogen). cDNA synthesis was performed with
total RNA (200 ng) using Super SuperScript III First -Strand
synthesis SuperMix for qRT-PCR (Invitrogen). qRT-PCR was
performed using TaqMan assay probes (Table S6) on an Applied
Biosystems 7900HT Sequence Detection System. All experiments
were performed using 8–10 mice/genotype with each sample
assayed in triplicate. The fold change for each gene was calculated
using the nnCt method normalized to Actin with data
represented as average 6 SEM. Statistical significance was
determined using a Student’s t-test.
Hematology and clinical chemistry
Blood samples were collected under isoflurane anesthesia by
retrobulbar puncture. Blood samples were divided in two portions
collected Li-heparin-coated sample tubes (Kabe, Nu ¨mbrecht-
Elsenroth, Germany) for clinical chemistry of plasma samples
and EDTA-coated sample tubes (Kabe, Nu ¨mbrecht-Elsenroth,
Germany) for hematological analyses, respectively.
EDTA-blood samples were analyzed for the complete blood
count using an abc-animal blood counter (Scil animals care
company, Viernheim, Germany) using predefined settings for
C57BL/6 mice. Number and size of red blood cells, white
blood cells, and platelets were measured by electrical impedance
and hemoglobin by spectrophotometry. Mean corpuscular
volume (MCV), mean platelet volume (MPV) and red blood
cell distribution width (RDW) were calculated directly from the
cell volume measurements. The hematocrit (HCT) was assessed
by multiplying the MCV with the red blood cell count. Mean
corpuscular hemoglobin (MCH) and mean corpuscular hemo-
globin concentrations (MCHC) were calculated from hemoglo-
bin/red blood cell count (MCH) and hemoglobin/hematocrit
(MCHC), respectively. Li-Heparin plasma was separated from
cells by centrifugation within two hours after collection. Samples
were diluted 1:2 with deionized water and analyzed for 24
clinical-chemical parameters using an AU400 autoanalyzer
(Olympus Germany, Hamburg, Germany) and reagents for
human samples provided Olympus Germany (Hamburg,
Germany) or Wako Chemicals GmbH (Neuss, Germany) in
case of non-esterified fatty acid concentrations (NEFA). Param-
eters measured included plasma iron concentration, ferritin
levels, transferrin concentration and unsaturated iron binding
capacity (UIBC). Transferrin saturation was calculated from
iron and UIBC values as percentage of iron level on total iron
binding capacity (TIBC = iron+UIBC). Data were statistically
analyzed with the level of significance set at p,0.05 by pair-
wise comparisons of the means by Welsh-Student’s t-test.
Protoporphyrin IX (PPIX) analysis
Tissue samples were collected in 150 mL water, sonicated, and
then an equal volume of 3 M HCl was added for a final
concentration of 1.5 M HCl. Acidified samples were then
incubated for 1 h at 37uC, spun at 13,000 RPM for 10 min,
and the supernatant quantified by HPLC using the method for
regular porphyrins [30].
Modified Hole Board (mHB)
The mHB experiments were carried out as previously
described [31,32]. In brief, for each trial an unfamiliar (a blue
plastic tube lid, diameter 2 cm, height 1 cm) and a copy of a
familiar object (metal cube, diameter 2 cm, height 1.5 cm;
remaining for 48 h in the home cage, removed 24 h before
testing) were placed into the same corner of the arena at a
distance of 2 cm. Each mouse was placed at the start position in
the same corner diametrical to the corner where the two objects
were placed, facing the board diagonally and was tested for
5 min in moderate light conditions (150 lux in the corners to
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arena was cleaned and disinfected. All trials were videotaped
and tracked by Ethovision 2.3 (Noldus, Wageningen, NL) for
calculation of horizontal locomotor activity parameters. The
movement detection threshold was set at a shift of the center of
gravity of the animal for at least 1 cm in a horizontal direction.
A hand-held computer was used by a trained observer to assess
line crossings, board entries, rearings on board, rearings in the
box, hole exploration, familiar and unfamiliar object explora-
tion, immobility, stretched attends (i.e. risk assessment behav-
iour), defecation and grooming. Data were analysed by use of
the Observer software 4.1 (Noldus, Wageningen, NL) with
respect to frequency, latency of first occurrence and duration in
% of total observation time. Any behaviour that did not occur
within the 5 min observation time was given the maximal
latency of 300 s. The object index was calculated as total
investigation time (s) at the unfamiliar object divided by the sum
of the total investigation time (s) at both objects.
Neurological testing
Neurological analysis was performed as previously described
[33]. Grip strength was measured by measuring maximal force the
mice applied to grid attached a force-meter (Bioseb, France) in
three consecutive trials. Fore paws and combined fore and hind
paw measurements were performed by allowing the mice to grasp
the grid before being slowly pulled away. Motor coordination was
evaluated by the latencies the animals stayed on a rotating rod,
acceleration from 4 to 40 rpm in five minutes. Mice were tested
four times with 15 minutes in between. For statistical analysis
linear models were used also considering body mass variations.
Nociception methods
In nociception, 18 Irp2
2/2 mice (9 males, 9 females) and 20 WT
animals (10 males and 10 females) were screened using a hot-plate
assay. A mouse was placed on a 28 cm diameter metal surface
maintained at 52+0.2uC surrounded by a 20 cm high Plexiglass
wall (TSE, Bad Homburg, Germany). Mice remained for
30 seconds on the plate or until they performed one of three
behaviors regarded as indicative of nociception: hind paw licking,
hind paw shake/flutter or jumping [34]. The latency of the first
sign of pain was compared for sex and genotype using a factorial
ANOVA.
Transmission electron microscopy
Animals (a subset of 5 Irp2KO and 4 WT mice) were
transcardially perfused with 50 ml ice cold PBS, prior to
perfusion with 70 ml of fixing solution (2.5% PFA, 2.5%
glutaraldehyde in PBS). Different brain regions were removed
and cut into 1 mm
3 cubes, which were postfixed in 2.5%
glutaraldehyde containing 0.1 M sodium cacodylate buffer
(pH 7.4) at 4uC overnight. Tissues were fixed in 2.5% electron
microscopy grade glutaraldehyde in 0.1 M sodium cacodylate
buffer pH 7.4 (Science Services, Munich, Germany), postfixed
in 2% aqueous osmium tetraoxide, dehydrated in gradual
ethanol (30–100%) and propylene oxide, embedded in Epon
(Merck, Darmstadt, Germany) and baked for 24 hours at 60uC.
Semi thin sections were cut and stained with toluidine blue.
Ultrathin sections of 50 nm were collected onto 200 mesh
copper grids, contrasted with uranyl acetate and lead citrate
before examination by transmission electron microscopy (Zeiss
EM 10 CR electron microscope, Carl Zeiss NTS GmbH,
Oberkochen, Germany).
Results and Discussion
Phenotypic characterization of Irp2
2/2 mice
Irp2
2/2 mice were generated by inserting a self-excision cassette
containing neomycin (Neo
r) linked to Cre-recombinase (Cre) into
exon 3 of the mouse Irp2 gene (Figure S1). Irp2
2/2 mice were
fertile and indistinguishable from wildtype (WT) littermates in
weight or appearance (data not shown). Irp2
2/2 mice showed mild
microcytic anemia characterized by reduced hemoglobin, hemat-
ocrit and mean corpuscular volume (Table S1). Transferrin
saturation, serum iron levels and total iron binding capacity were
unchanged in Irp2
2/2 and WT mice while serum ferritin levels
were markedly increased in Irp2
2/2 mice (WT, 58.1612.5 ng/ml
(n=9); Irp2
2/2, 218.667.3 ng/mL (n=10), p,0.001) (Table S2).
Irp2
2/2 mice also showed elevated levels of serum and liver
protoporphyrin IX (PPIX) and PPIX-containing aggregates in the
cystic, hepatic, and common bile ducts (Table S3 and Figure S2).
Irp2
2/2 mice displayed altered body iron distribution with total
iron content increased in duodenum, kidney and liver and
decreased in heart while total brain iron content is unchanged
(Table 1).
Ferritin and TfR1 have been shown to be dysregulated in liver,
duodenum and brain in two other distinct Irp2
2/2 mouse strains
[17,23,24]. Similarly, we find increased ferritin-L chain (Ftl1)
levels in brain (forebrain and cerebellum), liver, kidney and
duodenum and decreased TfR1 levels in brain, heart, liver and
kidney in Irp2
2/2 mice compared to WT mice (Figure 1A).
Ferritin-L and TfR1 levels are similar in Irp2
2/2 and WT spleen.
Irp2 RNA-binding activity and protein are not detected in Irp2
2/2
tissue lysates (Figure 1 A and B). A non-specific band is seen by
Western blot analysis that migrates close to Irp2 in some tissue
lysates (Figure 1A). Taken together, these phenotypes are in
agreement with those described for other Irp2
2/2 mouse strains in
which Irp2 deficiency causes microcytic anemia, erythropoietic
protoporphyria, and altered body iron distribution and expression
of ferritin and TfR1 [18,19,23].
Motor coordination/balance, locomotion and
nociception are impaired in Irp2
2/2 mice
The Irp2
2/2 strain generated by LaVaute et al. [17,35]
developed an adult-onset neurodegenerative movement disorder
at .6 months of age characterized by tremors, hind-limb
weakness, subtle kyphosis and abnormal gait. These mice
displayed poor self-grooming activity, and impaired muscular
strength and motor coordination when assayed by the hang test
and rotarod [17,35]. In contrast, Irp2
2/2 mice generated by Galy
et al. [19] showed no overt signs of neurodegeneration or impaired
muscle strength at 13–14 months of age. These mice displayed
reduced self-grooming activity consistent with a tendency toward
reduced rearings (vertical locomotor activity) and impaired motor
coordination/balance when challenged by the modified-Hole
Board and rotarod tests, respectively [26].
As our Irp2
2/2 mice at 45–63 weeks old did not display
tremors, kyphosis, or abnormal gait, we performed a battery of
tests to assess behavioral and neurological function. We used the
modified-Hole Board test to assay locomotor and exploratory
activities, arousal, memory and social affinity, the modified
SHIRPA test to assess neurological function, the grip strength
test to quantify muscular strength and the accelerating rotarod
to measure motor coordination and balance (Tables S4–S5).
Irp2
2/2 mice displayed an overall reduction in forward
locomotion, speed of movement and reduced vertical explor-
atory activities (rearing frequency and latency) (Figure 2A and
B). Rotarod performance was slighty impaired in aged Irp2
2/2
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week old Irp2
2/2 mice, suggesting a progressive phenotype
(Figure 2C and data not shown). The grip strength test (2-paws
and 4-paws) revealed that muscular strength was not impaired
in Irp2
2/2 mice (Figure 2D).
Nociception was also assessed in Irp2
2/2 and WT mice.
Irp2
2/2 mice showed no significant difference in the first pain
reaction (hind paw shaking) since they present with the same
reaction latency to heat stimuli as WT mice (Figure 2E).
However, Irp2
2/2 mice displayed a significantly longer reaction
latency in the second pain reaction (hind paw licking) (Figure 2E).
This finding indicated that Irp2
2/2 mice tolerated heat better
than WT mice when it was used as noxious stimulus. Increased
hind paw licking was also observed in 20-week old Irp2
2/2 mice,
indicating that this reaction was independent of age (data not
shown). Retarded reaction to thermal stimuli on the hotplate
could be a secondary effect of reduced motor abilities. If
impaired motor abilities influenced the pain reaction, however,
the same effect in both reactions, or at least in the first reaction
and not in the second reaction, would be observed. Altered
nociception heat tolerance was not reported for other Irp2
2/2
mice.
Impaired motor coordination and balance are consistent with
the Irp2
2/2 neurological phenotypes reported by Galy et al. [26]
and LaVaute et al. [17], although Irp2
2/2 mice generated by Galy
et al. [26] did not display horizontal locomotor impairments that
we observed in our Irp2
2/2 mice. Taken together, our data show
that Irp2 deficiency is associated with mildly impaired horizontal
locomotion, exploration, motor coordination/balance and noci-
ceptive heat tolerance.
Table 1. Tissue iron content of aged male Irp2
2/2 and WT mice.
Tissue WT (n=8) Irp2
2/2 (n=10)
Brain 1.9860.08 1.8460.07
Duodenum 6.0161.68 15.4161.76*
Liver 2.7760.21 5.8160.39***
Spleen 15.3962.44 12.5461.09
Heart 5.4960.05 4.92 60.13*
Kidney 2.2560.10 3.3760.15***
Lung 3.0160.40 2.8060.35
Total iron content was determined by inductively-coupled plasma optical emission spectroscopy (ICP-OES). Statistical analysis performed by Student’s paired t-test (*p,
0.05; ***p,0.001, mean (mg Fe/mg wet tissue weight) 61006 SEM). Ages of mice: WT, 64–75 weeks; Irp2
2/2, 49–71 weeks.
doi:10.1371/journal.pone.0098072.t001
Figure 1. Expression of iron homeostasis proteins in Irp2
2/2 and WT mice. A) Western blot analysis of tissue extracts from male Irp2
2/2 and
WT mice (n=3 mice/genotype) using antibodies to detect Irp2, Irp1, ferritin (Ftl1), TfR1 and b-actin (loading control). A non-specific band migrating
near Irp2 is observed in some Irp2
2/2 lysates. B) Irp1 and Irp2 RNA-binding activity in lysates was assayed by RNA electrophoretic mobility shift assay
using a
32P-labeled ferritin IRE as a probe. 0.5% b-mercaptoethanol was added to samples to assay total RNA-binding activity.
doi:10.1371/journal.pone.0098072.g001
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brain of Irp2
2/2 mice
Marked ferric iron accumulation was observed in oligoden-
drocyte soma and white matter axons in aged Irp2
2/2 mice
generated by LaVaute et al. [17,25]. Iron accumulated in the
cerebellum, caudate putamen, thalamus, substantia nigra and
colliculi, while the frontal cortex, globus pallidus and corpus
callosum were not affected [17,25,36]. Iron accumulation in
axons in cerebellar white matter was associated with axono-
pathy. Iron was also detected in neuronal cell bodies in gray
matter, including the thalamus, colliculi and deep cerebellar
neurons, and in Purkinje axons. In contrast, Galy et al. [26] did
not detect abnormal brain iron accumulation in their aged
Irp2
2/2 mice. Both groups analyzed aged mice (12–14 months
old) and used DAB-enhanced Perls’ iron staining method to
detect ferric iron. Both groups also reported no significant
differences in total brain iron [23] or total non-heme iron [26]
between Irp2
2/2 and WT mice.
Similar to previously reported global Irp2
2/2 mice, we found
no significant differences in total brain iron content between
Irp2
2/2 and WT mice using inductively-coupled optical
emission spectroscopy (Table 1). We next assessed ferric iron
histochemically in serial brain sections prepared from Irp2
2/2
(n=10) and WT (n=8) mice using DAB-enhanced Perls’ stain
(Files S1 and S2). Marked iron deposition was observed in
cortex, caudate putamen, thalamus, superior colliculus and
cerebellum as well as in other brain regions in Irp2
2/2 mice
(Figure 3 and Files S1 and S2). In cortex, iron accumulated in
small cells that have an eccentric nucleus characteristic of
oligodendrocyte morphology [37] and in axons (Figure 4A).
Iron accumulation was also observed in axon tracts and in
oligodendrocyte soma associated with striosomes, as well as in
oligodendrocytes scattered throughout the caudate putamen
(Figure 4B). Significant iron deposition was observed in the
superior colliculus (Figure 4C) and in the cerebellar white
matter and oligodendrocytes associated with white matter in
Irp2
2/2 mice (Figure 4E). Iron deposition in caudate putamen,
cerebellar white matter and colliculus, as well as other regions
(Files S1 and S2), is in agreement with Irp2
2/2 mice generated
by LaVaute et al. [17,25]. Unlike Irp2
2/2 mice generated by
LaVaute et al. [17,25], we did not detect increased iron
deposition in the substantia nigra of our Irp2
2/2 mice
(Figure 4D). WT and Irp2
2/2 mice used in our study were
older than mice used by Smith et al. [25] (,12 months old),
and it is possible that the high iron content in the substantia
nigra of our WT mice made it difficult to discern iron
differences between WT and Irp2
2/2 mice. We also found
significant iron deposition in the cerebral cortex and corpus
collosum of Irp2
2/2 mice, which was not observed by LaVaute
et al. [17] (Figures 3C and 4A).
Iron content is reduced in CA1 pyramidal neurons and in
Purkinje neurons of Irp2
2/2 mice
We next assessed Perls’ iron staining in hippocampal CA1
pyramidal neurons and in cerebellar Purkinje neurons in Irp2
2/2
and WT mice. Perls’ staining was significantly reduced in CA1
pyramidal neuronal soma and in their apical dendrites (Figure 5
and Figure S3). Purkinje neuronal soma in Irp2
2/2 mice showed a
slight, but significant reduction in iron content compared to WT
mice (Figure 5 and Figure S3).
A reported phenotype of Irp2
2/2 mice generated by LaVaute
et al. [17] is the degeneration and partial loss of Purkinje neurons
although this was not found in Irp2
2/2 mice generated by Galy
Figure 2. Locomotion, motor coordination and nociception are
impaired in Irp2
2/2 mice. Irp2
2/2 mice display reduced horizontal
locomotor activity (total distance traveled, number of turns, number of
total line crossings, mean velocity and angular velocity), and B) reduced
vertical exploratory activity (number of rearing and rearing latency)
assessed by the modified-Hole Board test [31]. C) Left panel,
performance of Irp2
2/2 and WT mice on the accelerating rotarod in
four trials on four consecutive trials with 15 min inter-trial-interval; right
panel, decreased mean latency of Irp2
2/2 mice to fall off the rotarod
(n=4 trial; p=0.055). D) 4-paw grip force test shows no difference in
muscular strength between Irp2
2/2 and WT mice. E) Hot plate test
shows increased hind paw licking in Irp2
2/2 mice. Data are given as the
mean 6 SEM; *p,0.05;
**p,0.01, ***p,0.001, relative to WT; WT (n=9)
and Irp2
2/2 (n=10).
doi:10.1371/journal.pone.0098072.g002
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2/2 and WT cerebellar sections with
calbindin antibody (Purkinje cell specific) and found no abnor-
malities in Purkinje cell morphology or cell number in Irp2
2/2
mice (WT, 3.16 cells/inch 60.267; Irp2
2/2, 3.57 cells/inch
60.232; p=0.264) (Figure 6A). Ultrastructural analysis of
substantia nigra, caudate putamen, cerebellum, cortex, hippo-
campus and hypothalamus did not reveal pathological alterations
in these regions except for the presence of age-related lipofuscin
deposits in neurons that are detected in aged WT and Irp2
2/2
mice (Figure S4 and data not shown). Myelinization also appeared
normal in Irp2
2/2 mice evaluated by Luxol Fast Blue staining
(Figure S5).
The reduction in Perls’ staining in Irp2
2/2 CA1 pyramidal
and Purkinje neurons suggests that these neurons may be iron
deficient. Because neurons acquire iron primarily by TfR1
[38,39], the reduction in TfR1 abundance in Irp2
2/2 cerebellar
and forebrain lysates compared to WT is consistent with
reduced transferrin-dependent iron uptake (Figure 1A). In
contrast to TfR1, ferritin expression is increased in Irp2
2/2
cerebellar and forebrain lysates (Figure 1A). We next assessed
ferritin expression in neurons in Irp2
2/2 and WT sections from
cerebellum, caudate putamen and hippocampus by double
immunofluorescence using a ferritin antibody in combination
with antibodies specific to neurons (NeuN) and to Purkinje
neurons (calbindin). Ferritin immunoreactivity was similar in
Irp2
2/2 and WT Purkinje neurons (Figure 6B), but was
increased in Irp2
2/2 CA1 pyramidal neurons and in neurons
in the caudate putamen (Figure 6C and D). We were not able
to assess TfR1 immunostaining in these sections due to
technical difficulties. Taken together, these data suggest that
the reduction in TfR1 expression and increased ferritin
expression in Irp2
2/2 mice could lead to reduced iron uptake
and increased iron storage, thus causing cellular iron deficiency.
While notable neuronal pathology was not observed in Irp2
2/2
brain, we suggest that neuronal iron deficiency may cause
cellular dysfunction that contributes to the neurological and
behavioral deficits in Irp2
2/2 mice.
Conclusions
In conclusion, our data show that mice with a global Irp2
deficiency recapitulate the main features of other Irp2 deficient
mouse models such as microcytic anemia, erythropoietic proto-
porphyria, altered body iron distribution and altered expression of
ferritin and TfR1 in tissues. Our aged Irp2
2/2 mice did not
exhibit, tremor, ataxia, bradykinesia and postural abnormalities as
described by LaVaute et al. [17], but did display mild impairments
in horizontal locomotion, rearing activity, balance/motor coordi-
nation and nociceptive heat tolerance when assayed by specific
tests. Our data are consistent with impaired motor and balance
coordination reported for the other two strains of Irp2
2/2 mice
and with reduced rearing activity reported for Irp2
2/2 mice
generated by Galy et al. [26]. The reduced rearing activity in our
Irp2
2/2 mice is consistent with a slight reduction in self-grooming
(which could imply a reduction in vertical locomotion), although
this did not reach statistical significance, and is similar to other
Irp2
2/2 mice that exhibited a significant reduction in self-
grooming activity [17,26].
Our Irp2
2/2 mice showed distinctive features not reported
for other Irp2
2/2 mice. The modified hole board test revealed
that Irp2
2/2 mice displayed an overall reduction in locomotor
activity characterized by decreased total distance moved, line
crossings, turning frequency and movement velocity. This
combination of mild hypoactivity and reduced rearing in our
Irp2
2/2 mice suggests reduced exploratory motivation. Galy
et al. [26] also used the modified hole board test, but did not
observe impaired horizontal locomotion in their 13–14 month
old Irp2
2/2 mice. We also found that Irp2
2/2 mice showed a
hypoalgesic phenotype as assessed by the hot plate test that was
independent of age. Our Irp2
2/2 mice develop diabetes (EAL,
SN, CPA and KBZ, unpublished observation), and it is possible
that hypoalgesia is a consequence of impaired glucose tolerance.
Another novel phenotype in our Irp2
2/2 mice is the presence of
PPIX containing aggregates in the cystic, hepatic, and common
bile ducts. Cooperman et al. [23] showed increased synthesis of
the heme biosynthetic enzyme erythroid aminolevulinate
synthase 2 (Alas2), which contains an IRE in the 59 untranslated
region, and reduced expression of TfR1 in Irp2
2/2 erythroid
Figure 3. Iron accumulates in specific brain regions of Irp2
2/2
mice. Coronal sections from male Irp2
2/2 and WT brains from rostral
(top) to caudal (bottom) were selected to show iron accumulation in
specific regions of brain. Ferric iron was detected using DAB-enhanced
Perls’ stain. Ctx cortex, CB cerebellum, CPu caudate putamen, cc corpus
collosum, Gp globus pallidus, Hy hypothalamus, PAG, periaqueductal
gray; SC superior colliculus, SN substantia nigra and Thl thalamus.
doi:10.1371/journal.pone.0098072.g003
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deficiency and reduced Tf-dependent iron uptake likely results
in elevated PPIX levels we observed in the serum, liver and bile
ducts. Whether other Irp2
2/2 mice show PPIX aggregates in
the bile ducts remains to be determined.
An explanation for the varied neurodegenerative phenotypes
in the different Irp2
2/2 models is not clear, but it is known that
neurological and behavioral phenotypes can be sensitive to
genetic background differences and gene targeting strategies
[40–42]. Our mice were generated using 129/Sv-CP ES cell
line and were backcrossed to C57BL/6J mice for five
generations, and those of Galy et al. [19,26] were generated
using the 129P2/OlaHsd ES cell line and backcrossed to
C57BL/6J mice for three generations. Irp2
2/2 mice generated
by LaVaute et al. [17] are mixed genetic background consisting
of C57BL/6 and B129S4/SVJ. In addition, different targeting
approaches were used to generate Irp2
2/2 mice. LaVaute et al.
[17] generated a global model of Irp2 deficiency by insertion of
a PGK-neomycin gene into exon 3/4 of Irp2 gene. Galy et al.
[19] generated conditional alleles of Irp2 by insertion of a b-Geo
cassette flanked by Frt sites into intron 2 of the Irp2 gene and
was co-inserted with LoxP sites flanking exon 3. Cre-mediated
excision of exon 3 generated a null allele. Our Irp2
2/2 mice
were generated by the insertion of a self-excision cassette
containing neomycin linked to Cre-recombinase into exon 3 of
the mouse Irp2 gene. Targeting strategies can lead to different
phenotypes due to silencing or activation of flanking genes
caused by the retention of selection cassettes, generation of
truncated gene products with biological activity or inactivation
of non-coding RNAs with the targeted locus [43,44]. The
expression of neighboring genes close to the Irp2 locus was not
altered in Irp2
2/2 mice [19] and we did not identify annotated
non-coding RNAs located within the Irp2 locus. The differences
in neurological and behavioral phenotypes in Irp2
2/2 mice
could also be affected by environmental conditions (food,
altitude or environmental stimulation) [44] and natural variation
Figure 4. Iron accumulates in axons and oliogodendrocyte cell bodies of Irp2
2/2 mice. Increased DAB-enhanced Perls’ iron stain is
observed in small cells that have an eccentric nucleus characteristic of oliogodendrocyte morphology [37] and in axons in A) cerebral cortex, B)
caudate putamen, C) superior colliculus, D) substantia nigra, and E) cerebellum. Arrows, oligodendrocytes; S, striosomes; wm, white matter; gl, granule
layer. Scale bars: 50 mm and 500 mm.
doi:10.1371/journal.pone.0098072.g004
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reasons for the different neurological and behavioral phenotypes
observed in Irp2
2/2 mice are not completely understood, but it
is likely that the genetic background and the targeting strategies
used to generate Irp2
2/2 are important components.
Ultrastructural analyses of several regions of brain from Irp2
2/2
mice reveal normal neuronal morphology and calbindin staining
of cerebellar sections show no loss of Purkinje cells. However,
marked iron accumulation is observed in white matter and in
oligodendrocytes associated with white matter throughout the
brain consistent with studies from LaVaute et al. [17]. Oligoden-
drocytes normally contain high levels of iron and express high
levels of ferritin. The high iron content of oligodendrocytes is
thought to be required for myelin production [46]. Myelinization
Figure 5. Iron is reduced in Purkinje neurons and in CA1
pyramidal neurons of Irp2
2/2 mice. A) Perls’ DAB-enhanced iron
staining in CA1 pyramidal neurons and Purkinje neurons in Irp2
2/2 and
WT mice (Pkj, Purkinje; gl, granular layer; wm, white matter). B)
Quantification of Perls’ staining of images in (A) was carried out by
measuring staining intensity in a defined subsection of brains from
Irp2
2/2 (n=10) and WT (n=8) (Figure S3). Data are given as the mean
6 SEM; *p,0.05; ***p,0.001 relative to WT. Scale bars: 25 mm and
50 mm.
doi:10.1371/journal.pone.0098072.g005
Figure 6. Ferritin expression is increased in Irp2
2/2 neurons.
Double immunofluorescence labeling of brain sections from male Irp2
2/
2 and WT mice using ferritin antibody with either calbindin (Purkinje
specific) or NeuN (neuronal nuclei) antibodies. A) Calbindin immuno-
fluorescence shows that Purkinje cell number and morphology (yellow
arrows, processes), are normal in Irp2
2/2 cerebellum. B) Ferritin and
calbindin double immunofluorescence of cerebellum shows similar
ferritin expression in Irp2
2/2 and WT Purkinje neurons. C) Ferritin and
NeuN double immunofluorescence of hippocampal CA1 pyramidal cell
layer, and D) caudate putamen shows increased ferritin expression in
neuronal cell bodies (yellow arrows)o fIrp2
2/2 mice compared to WT
mice. Increased ferritin staining is observed in the neuropil in the
hippocampus and caudate putamen of Irp2
2/2 mice. Scale bars: 50 mm.
doi:10.1371/journal.pone.0098072.g006
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2/2 brain, suggesting that high iron content is
not detrimental to oligodendrocyte function.
A notable difference between our Irp2
2/2 mice and those of
LaVaute et al. [17] is the significant iron accumulation in
oligodendroycytes in the cortex of Irp2
2/2 mice. We also found
that CA1 pyramidal neurons and Purkinje neurons are iron
deprived. Since neurons primarily acquire iron by TfR1,
reduced TfR1 and increased ferritin expression in Irp2
2/2
brain would reduce transferrin-dependent iron uptake in parallel
with an increase ferritin iron sequestration, eventually leading to
cellular iron deficiency. Although we did not find pathological
evidence of neurodegeneration, it is possible that cellular iron
deficiency in neurons causes cellular dysfunction that leads to
mild deficits in locomotion, motor coordination and nociception.
This idea is consistent with a recent study showing that Irp2
2/2
mice develop motor neuron disease characterized by increased
ferritin and decreased TfR1 expression in motor neurons,
reduced spinal cord iron and impaired mitochondrial function
[47]. Taken together, these studies suggest that abnormal brain
iron metabolism due to Irp2 deficiency disrupts cellular function
and leads to mild neurological, behavioral and nociception
impairments.
Supporting Information
Figure S1 Generation of Irp2
2/2 mice. (A1) Schematic
representation of exons I-VII of the murine Irp2 (Ireb2) gene. Exons
(black boxes) and introns (black lines). (A2) Schematic diagram of
the targeting vector. A genomic clone (p11.1) containing exons III-
VII encoding amino acids 37–233 in Irp2 was isolated from a
mouse 129 genomic library. A ScaI-PstI fragment from p11.1
(dotted lines) was subcloned into Bluescript SK to generate the
targeting vector. A self-excision cassette containing neomycin (Neo
r)
linked to Cre-recombinase (Cre) was inserted into exon III of the
mouse Irp2 gene [48]. This cassette (pACN) contains the Cre gene
(driven by the testes-specific angiotensin-converting enzyme (tACE
promoter) linked to the Neo
r gene (driven by the polymerase II
promoter), and is flanked by loxP sites allowing for excision of Neo
r
as it passes through the male germ line. This cassette also contains
human hIrp1-Flag sequence fused in-frame to exon III of Irp2 for
experiments related to functional replacement of Irp2 with Irp1.
For reasons discussed below, Irp1-Flag was not detected in any
tissues examined. Thymidine kinase (Tk1 and Tk2) genes were
inserted at the 59 and 39 ends of the targeting vector to select
against random insertion. (A3) Predicted structure of the Irp2
replacement allele after homologous recombination and germ-line
induced self-excision. The targeting vector was electroporated into
R1 ES cell line (129/Sv-CP) and heterozygous cells in which a
homologous recombination event occurred were identified by
PCR and Southern blot analysis of ScaI-digested DNA probed
with 39 EXT and Neo probes (Figure S1B, left panels). A targeted
ES cell clone (F4) was microinjected into C57BL/6J blastocysts to
generate chimeric animals. A chimera was bred to C57BL/6J
mice and resulting chimeric progeny was identified by coat color
and for the presence of the Irp2
+/2 allele by PCR and Southern
blotting. Heterozygous offspring were backcrossed five times to the
C57BL/6J background and intercrossed to generate homozygous
Irp2
2/2 mice. (B) Germline transmission of the Neo-deleted allele
was confirmed by Southern blot analysis of Sca1-digested genomic
DNA from Irp2
+/+, Irp2
+/2 and Irp2
2/2 mice probed with the 39
EXT probe and shows a WT band (10 kb) in Irp2
+/+, a WT and a
mutant band (7 kb) in Irp2
+/2 and a mutant band in Irp2
2/2
(7 kb). The absence of the Neo
r/Cre cassette was confirmed by
probing the blot with a Neo probe (not shown). PCR genotyping
was performed using tail DNA biopsies (Table S9). (C) Quanti-
tative RT-PCR showed Irp2 mRNA was not detected in Irp2
2/2
E9.5-E10.5 lysates and reduced 2-fold in Irp2
+/2 lysates compared
to WT lysates (TaqMan assay: Irp2 exons 3–4). hIrp1-Flag mRNA
was not expressed in Irp2
+/+ lysates, but is expressed in Irp2
+/2 and
Irp2
2/2 lysates (TaqMan assay: hIrp1). A TaqMan assay
corresponding to exons 1–2 (common to both Irp2 and hIrp1-Flag)
showed that hIrp1-Flag mRNA expression is , 80% of endogenous
Irp2 mRNA. (D) Although hIrp1-Flag mRNA was detected in
Irp2
2/2 lysates, no hIrp1-Flag protein or RNA-binding activity
was detected by Western blot analysis or by RNA-EMSA,
respectively, in E9.5-E10.5 lysates or any tissue examined (data
not shown). The lack of hIrp1-Flag expression is likely due to faulty
translation and/or increased turnover of the hIrp1-Flag protein. If
hIrp1-Flag is expressed at low levels, the RNA-binding activity of
this recombinant protein is not sufficient to compensate for loss of
Irp2 protein since Irp2
2/2 mice display altered body iron
distribution (Table 1), microcytic anemia (Table S1), and
inappropriate regulation of Irp2 targets ferritin and TfR1
(Figure 1) in agreement with published phenotypes of Irp2
2/2
mice [17,23,24]. TaqMan assays used in these experiments can be
found in Table S6.
(TIF)
Figure S2 Presence of PPIX-containing granules in the
common bile duct of Irp2
2/2 mice. Black arrows indicate
PPIX-containing granules in Irp2
2/2 (C) mice. B and D are
magnified images of A and C. PPIX-containing granules are found
in all male and female Irp2
2/2 mice examined at 2.5- to 18-
months of age.
(TIF)
Figure S3 DAB-enhanced Perls’ iron staining of hippo-
campus and cerebellum of aged Irp2
2/2 and WT mice.
Coronal sections of hippocampus (A) (slide 41) and cerebellum (B)
(slide 58) used for quantification of iron in CA1 pyramidal neurons
and in Purkinje neurons in Figure 5. Dotted boxes indicate the
WT (6B-4) and the Irp2
2/2 (6A-3) mice used for DAB-enhanced
Perls’ staining in File S1 and File S2. Ages of male mice: WT, 65–
71 weeks; Irp2
2/2, 46–53 weeks.
(TIF)
Figure S4 Ultrastructual analysis of brain regions of
aged Irp2
2/2 and WT mice shows no evidence of
neurodegeneration. Electron micrographs of the caudate
putamen, substantia nigra and cerebellum of Irp2
2/2 and WT
mice. Myelinized (white arrows) and non-myelinized (black arrow)
axons are shown. No pathological alterations were evident in these
brain regions. Similar amounts of lipofuscin deposits (L) were
detected in both Irp2
2/2 and WT mice. This can be accounted as
a normal finding since lipofuscin accumulates with age in many
organs including brain. Representative images are shown from
WT (n=4) and Irp2
2/2 (n=5) mice. Ages of male mice: WT, 65–
71 weeks; Irp2
2/2 46–53 weeks. Scale bars are indicated.
(TIF)
Figure S5 Luxol Fast Blue staining of brains of aged
Irp2
2/2 and WT mice shows no difference in myeliniza-
tion. Representative images are shown from WT (n=4) and
Irp2
2/2 (n=5) mice. Ages of male mice: WT, 65–71 weeks; Irp2
2/
2, 46–53 weeks.
(TIF)
Table S1 Hematological parameters of aged male WT
and Irp2
2/2 mice.
(DOCX)
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Irp2
2/2 mice.
(DOCX)
Table S3 Protoporphyrin IX (PPIX) levels of 12-month
old male WT and Irp2
2/2 mice.
(DOCX)
Table S4 Results of behavioral observation in the
modified-Hole Board test.
(DOCX)
Table S5 Video-tracking results regarding locomotor
behavior.
(DOCX)
Table S6 List of primers and TaqMan assays used for
genotyping and qRT-PCR.
(DOCX)
File S1 DAB-enhanced Perls’ iron staining of coronal
sections of WT (6B-4) brains. Images (10–66) are from rostral
to caudal. High resolution files are available from the correspond-
ing author.
(ZIP)
File S2 DAB-enhanced Perls’ iron staining of coronal
sections of Irp2
2/2 (6A-3) brains. Images (10–66) are from
rostral to caudal. High resolution files are available from the
corresponding author.
(ZIP)
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